All In Biotech

Free tool

FAERS Monitor: Balversa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212018 or its brand name (Balversa, Erdafitinib). Reports on generic versions are filed under their own applications.

Reports

1,247

Serious

919

74% of reports

Hospitalization

263

Death reported

349

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death272
  • off label use104
  • diarrhoea100
  • stomatitis82
  • onycholysis58
  • fatigue53
  • hyperphosphataemia53
  • nail disorder53
  • dry mouth46
  • nail discolouration45
  • dry eye43
  • disease progression42
  • mucosal inflammation38
  • onychomadesis38
  • decreased appetite37

Reports by year received

View as table
YearReports
20181
201979
2020234
2021193
2022246
2023142
2024154
2025106
202692

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,912 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
onycholysisSignal58650.2503.235,582
hyperphosphataemiaSignal53426.3326.421,523
nail discolourationSignal45195.3146.38,410
onychomadesisSignal38154.1112.55,578
nail disorderSignal53102.878.95,212
mucosal inflammationSignal3824.517.9834
stomatitisSignal8222.818.51,693
dry eyeSignal4314.510.8530
dry mouthSignal469.67.2346
disease progressionSignal426.04.4170
deathSignal2725.34.8992
decreased appetiteSignal372.72.038
diarrhoeaSignal1002.62.2101
off label useSignal1042.01.753
fatigue531.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.